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Protein conformationThe zinc-dependent matrix metalloproteinases (MMPs) belong to a large family of structurally homologous
enzymes. These enzymes are involved in a wide variety of biological processes ranging from physiological cell
proliferation and differentiation to pathological states associated with tumor metastasis, inﬂammation, tissue
degeneration, and cell death. Controlling the enzymatic activity of speciﬁc individual MMPs by antagonist
molecules is highly desirable, ﬁrst, for studying their individual roles, and second as potential therapeutic
agents. However, blocking the enzymatic activity with synthetic small inhibitors appears to be an extremely
difﬁcult task. Thus, this is an unmet need presumably due to the high structural homology between MMP
catalytic domains. Recent reports have recognized a potential role for exosite or allosteric protein regions,
distinct from the extended catalytic pocket, in mediating MMP activation and substrate hydrolysis. This raises
the possibility that MMP enzymatic and non-enzymatic activities may be modiﬁed via antagonist molecules
targeted to such allosteric sites or to alternative enzyme domains. In this review, we discuss the structural
and functional bases for potential allosteric control of MMPs and highlight potential alternative enzyme
domains as targets for designing highly selective MMP inhibitors.© 2009 Published by Elsevier B.V.1. IntroductionMatrix metalloproteinases (MMPs) are known to regulate and
control many physiological and pathological processes in vivo. The
zinc-dependent endopeptidases belonging to the family of matrix
metalloproteinases (MMPs) have been shown to play key roles in
inﬂammation, multiple sclerosis, cardiovascular diseases, autoim-
mune diseases, cancer, angiogenesis, and tumor metastasis [1–4]. The
MMPs comprise a large family of secreted or membrane-bound
proteases. Beyond their classical connective-tissue-remodeling func-
tions, MMPs are known to precisely regulate the function of bioactive
molecules by proteolytic processing [5]. Therefore, their potential
effects on cell behavior are multifarious [6,7]. The molecular bases
leading to these functional interactions with various proteins and
ligands are largely poorly understood. In addition, the involvement of
MMPs in awide range of biological processes ranging frommatrix and
cell functions to expression of information molecules complicates and
compromises their ability to dissect their biological functions. Never-
theless, a detailed molecular mechanistic understanding is critical for
revealing their biological function. Tremendous efforts have been
invested over the years to study the structure and functional role
underlying the modular domain organization of MMPs. Elucidation of
the three-dimensional structural models of a wide selection of MMPs
provided important insights into their molecular nature. Thelsevier B.V.structural homology of the catalytic domains among members of
the MMP family strikingly suggests that their speciﬁc molecular
interactions may be guided by the chemical, biophysical, or molecular
nature of their modular structure requiring the participation of
multiple domains.1.1. Structural features of MMPs
MMPs are members of the metzincin group of proteases, which
are named after the catalytically essential zinc ion and the conserved
Met residue at the active site [8,9]. All MMPs are secreted as latent
pro-enzymes, whose activation involves the loss of an N-terminal
pro-peptide sequence of about 80 amino acids [10]. The pro-domain
contains a “cysteine switch” PRCGXPD consensus sequence [11]. The
sulfhydryl group of the conserved cysteine residue in this sequence
coordinates to the catalytic zinc ion to maintain enzyme latency
[12,13]. Thus, MMP activity is suppressed as a result of zinc-cysteine
coordination and pro-peptide domain occlusion of the active site.
MMPs share a fairly similar catalytic domain (160–170 amino acids)
that includes a highly conserved HExxHxxGxxH catalytic zinc
binding motif (structural studies on isolated catalytic domains
indicate the presence of an additional highly conserved structural
zinc site) [10]. The catalytic zinc is situated in a large and relatively
shallow cleft facilitating the binding of substrates and inhibitors
[14,15]. Figs. 1 and 2 provide an overview on the modular domain
organization of the MMP family and their atomic structure.
Fig. 1.Modular domain organization of MMPs. All MMPs share similar domain organization. The N-terminal domains of MMPs contain a signal peptide, a pro-peptide, and a catalytic
domain with a conserved zinc binding motif. The conserved cysteine switch residue resides on the pro-peptide and binds the catalytic zinc ion in the zymogen form. The gelatinases
contain three ﬁbronectin repeats for the binding of gelatin. A linker domain of various lengths connects the N-terminal to the C-terminal hemopexin domain (absent in MMP-7). The
MT-MMPs are bound to the cell surface through a C-terminal membrane anchor domain.
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terminal hemopexin domain (200 amino acids), which is usually
connected to the MMP catalytic domain through a linker of variable
size (2–72 amino acids). It encodes a four-bladed β-propeller
structure that mediates protein–protein/substrate interactions
[16,17]. (2) The MMP-2 and MMP-9 (known as gelatinases) are
unique in having three ﬁbronectin type II repeats (165 amino acids),
which mediate binding to collagens and gelatins [18,19]. (3)
Membrane-type MMPs (enumerated MT1 to MT6-MMP); these
MMPs are attached to the cell surface via a transmembrane domain
or GPI anchor [20].
1.2. Activation of MMPs
The in vivo catalytic activity of MMPs is regulated at four levels: gene
expression, compartmentalization (i.e., pericellular accumulation of
enzyme), proenzyme (or zymogen)activation, andenzyme inhibition; it
is also controlled by substrate availability and afﬁnity (reviewed in [21]).
MMP zymogens (or pro-MMPs) are thought to be activated in vivo by
proteases including tissue kallikrein, trypsin, and other MMPs [21], and
are activated in vitro by chemical agents such as aminophenyl mercuric
acetate and other S-reactive agents, as well as reactive oxygen species
and detergents [22–24]. The underlyingmodes of activation involve the
dissociation of the cysteine from the active site zinc atom and its
replacement by water, with concomitant exposure of the active site by
sequential proteolytic removal of the pro-peptide [12,25].
1.3. Endogenous inhibition of MMPs
The in vivo proteolytic activity of MMPs is regulated by four
endogenous inhibitors designated as Tissue Inhibitors of Metallopro-teinases (TIMP-1–TIMP-4). These proteins exhibit high sequence
identity and similarity [26,27]. Remarkably, the N-terminal domains
can fold independently and carry the full inhibitory activity toward
their target MMPs [28,29]. TIMPs inhibit MMPs by inserting a
conserved anchor into the active site of the target MMP, which
directly coordinates the catalytic zinc ion via an N-terminal cysteine
residue. This conserved N-terminal segment binds the extended S1′
pocket in a substrate-like manner [30]. Modiﬁcations that weaken the
metal ion chelating ability of TIMPs, via the addition of an extra Ala at
the N-terminus, or carbamylation of the N-terminal amino group,
inactivate TIMPs with respect toMMP inhibition [31,32]. This conﬁrms
the mechanistic importance of metal chelation by the N-terminal
amino group in metalloproteinase inhibitory activity [30,33].
The association of MMPs with a variety of pathological states has
stimulated impressive efforts over the past 20 years to develop
synthetic compounds capable of potently and selectively blocking the
uncontrolled activity of these enzymes under disease conditions
[34,35]. However, despite tremendous efforts over the past decade,
only a few selective and effective drugs with desired properties have
emerged for inhibiting individual MMPs [34–37]. Several reasons
were postulated to explain the poor performance of broad-spectrum
MMP inhibitors in clinical trials. These include side effects owing to
inhibition of closely related enzymes, such as the adamalysins
(ADAMs), lack of speciﬁcity, poor pharmacokinetics, toxicity, and
the inability to assess inhibitory efﬁcacy [38–41]. In addition, recent
studies have shown that the role of MMPs is much more complex
than that derived from their direct degradative action on ECM
components [5]. Growth-factor receptors, cell adhesion molecules,
chemokines, cytokines, apoptotic ligands, and angiogenic factors are
just some examples of the diversity of substrates targeted by
individual MMPs. These ﬁndings suggest the absolute need for tight
Fig. 2. The full-length three-dimensional X-ray crystallography structure of pro-MMP-2
(PDB code 1ck7). The ﬁrst atomic structure of full-length pro-MMP-2 [12] represents
the enzyme modular domain organization. The structural and catalytic zinc ions are
presented as orange and red spheres respectively. The catalytic zinc ion is ligated to
three conserved histidines and cysteine residues. The pro-domain is depicted as green
ribbon, the ﬁbronectin repeats are presented in red and the hemopexin domain is
presented in dark blue. The catalytic domain is presented in gray facing the extended
catalytic pocket. Pro-MMP-2 contains a 22 amino acid-long linker domain not resolved
in the crystal structure. Importantly, the linker domain in MMPs spans different lengths
ranging from 5 to 64 amino acids with different amino acid compositions.
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protease levels may favor tissue-destructive processes such as those
taking place in cancer, whereas speciﬁc protease deﬁciencies may
lead to the development of many other pathological conditions [4].
Remarkably, the core of the problem remains the issue of inhibitor
selectivity [2,4,42,43]. Hence, attaining the ability to block individual
MMPs under pathological conditions is the focus of research in this
ﬁeld.
It has become more appreciated that further understanding of
structural characteristic of full-length MMPs, and their complexes
with substrates, signaling molecules, and protein partners reveals
critical functional information that may be further utilized for
designing highly selective inhibitors. Along these lines, a growing
trend in the ﬁeld of MMPs emphasizes the importance of targeting not
only the enzyme catalytic zinc site but also distal surface residues
residing away from the catalytic machinery as well as the other MMP
accessory domains. For such strategies to be successful, it is essential
to increase our basic understanding of the structural and biophysical
aspects governing MMPmolecular mechanisms. This study overviews
the advancement in our current understanding of MMP molecular
structures, dynamics, and interactions with ECM macromolecules.
Here we argue that MMPs are regulated by allosteric molecular
mechanisms mediated by their substrates or protein partners. Thus,
identiﬁcation and characterization of “MMP allosteric sites” may
represent novel drug targets.
2. Modular organization of MMPs and their allosteric control
The term allostery here refers to regulatory sites located on the
surface of the enzyme, distant from an active site that may inﬂuenceenzyme activity by affecting its optimal conformation. Relevant to
MMPs as modular enzymes, the term “allosteric control” also refers to
any interactions of the enzyme mediated via its distal domains, e.g.,
linker or hemopexin domains. Naturemakes extensive use of protein–
protein and protein–ligand allosteric interactions to regulate the
activities of proteins and enzymes. Accumulating knowledge indicates
that enzymatic catalysis is controlled by the synergy between protein
structure and side chain conformation dynamics mediated by
macromolecule interactions [44–46]. The classical allosteric enzyme,
hemoglobinwas ﬁrst described as an oligomer [47]; however, recently
it has been shown that not only oligomeric proteins but monomeric
proteins as well may exhibit allosteric effects of functional importance
[14,48]. Conformational changes may occur in the protein structure
owing to its dynamic nature and these changes may play an important
role in allostery. All proteins exist as populations of conformations
according to the Boltzmann distribution and any population shift due
to a conformational change may be the basis for allosteric regulation.
In fact, it has been suggested that all proteins have intrinsic allostery
[49]. Naturally, proteins and enzymes possessing multidomain
organization or signiﬁcant protein side chain ﬂexibility are prone to
allosteric regulation by their substrates or effectors.
Along these lines, the molecular nature and the modular domain
organization of MMPs enable the utilization of allosteric molecular
control in mediating their functional activities. This argument is
inspired primarily by recent reports of full-length structural models of
MMP-9 and MMP-12 determined in solution. Whereas the X-ray
structures of full-length MMP-1 [50,51] and MMP-2 [12] suggest a
conserved and well-deﬁned spatial relationship between the two
domains, structural spectroscopic analyses of MMP-9 and MMP-12
possessing 64- and 14 amino acid-long linker domains highlight the
conformation variability of the two terminal domains of MMP-9 and
MMP-12. Speciﬁcally, using a combination of small-angle X-ray
scattering (SAXS) with single-molecule imaging atomic force micro-
scopy (AFM), Rosenblum et al. [52] demonstrated that pro-MMP-9
possesses an elongated structure consisting of two terminal globular
domains connected by an unstructured and ﬂexible 30-Å-long O-
glycosylated (OG) domain. The degree of the OG domain ﬂexibility
was statistically evaluated from the various protein conformations
detected by single-molecule imaging. Such ﬂexibility enables the
enzyme to retain many varied conformations and to facilitate
independent movements of the terminal domains. Similarly, the
full-length structure of MMP-12 was studied in solution (NMR and
SAXS) and in the solid state (X-ray), showing that the hemopexin-like
and the catalytic domains experience conformational freedom with
respect to each other [53]. Remarkably, both the MMP-9 and MMP-12
molecules adopt various compact protein conformations with differ-
ent relative orientations of the two domains, whereas other
conformations are signiﬁcantly more extended. This indicates that
the X-ray structure does not provide complete information on the
conformation of the protein in solution.
How can such domain conformational variability contribute to
function? In the case of MMP-9, it has been suggested that the long
and ﬂexible OG domain may mediate protein-substrate interactions
by allowing the independent movement of the enzyme terminal
domains [52]. Such independent domain movements were also pro-
posed to mediate enzyme translocation on collagen ﬁbrils [54–56]
and to promote peptide hydrolysis of intact collagen molecules. Such
domain ﬂexibility may be rationalized for most MMPs as appeared by
the amino acid composition (containing prolines and glycines) and
the various lengths of their linker domains (Fig. 3). In addition, it was
proposed that domain ﬂexibility can contribute to MMP zymogen
activation and the cleavage of the pro-domain via promoting long-
range conformational transitions induced by the binding of the
activator proteins or ligand [25,57,58]. Finally, reorientation of the
hemopexin domain with respect to the catalytic domain during
catalysis was proposed to play critical role in collagen hydrolysis by
Fig. 3. Bioinformatic comparison of length and amino acid composition of MMP linkers.
Multiple sequence alignment of human MMPs (X-axis) reveals the difference in linker
length and composition (Y-axis). The linker of MMP-9 appears to be exceptionally long
among the soluble MMP subfamilies: gelatinases, collagenases and stromelysins. The
amino acid composition of proline and glycine was checked owing to their high
propensity to interferewith the formation of secondary structures, leading to disordered
regions. Inspection of Threonine and Serine content was preformed since these residues
are a potential site for glycosylation. Remarkably, this type of analysis indicates that
most MMPs exhibit potential ﬂexible nature mediated by their linker domain.
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teric control was proposed to be instrumental in dimer formation via
the hemopexin and linker domains in MT1-MMP and MMP-9 [60,61],
leading to biological function. Next, we will review some evidence
suggesting the existence of allosteric control in MMPs during their
various activities including zymogen activation, oligomerization,
substrate hydrolysis, and inhibition.
3. Molecular control of MMPs via exosites
3.1. Molecular regulation of MMP activation via exosite protein–ligand
interactions
A key feature in regulating MMP enzymatic activity is the
conversion of the zymogen form into an active proteinase. As
described above, MMPs are produced as pro-enzymes and kept in a
catalytically inactive state by the interaction of the pro-domain-
conserved cysteine residue with the catalytic zinc ion [11]. It is widely
accepted that this process, termed “cysteine switch” is a general
requirement in the activation step of all pro-MMPs. Enzyme activation
is thought to be mediated by three main mechanisms: (1) removal of
the pro-domain by direct proteolytic cleavage of the pro-domain, (2)
chemical modiﬁcation of the cysteine residue by nonphysiological
agents and free radicals, and (3) allosteric perturbation of the
zymogen (reviewed in [21]). Importantly, the molecular details of
how pro-MMPs are activated directly or allosterically are largely
unknown.
Early work by Nagase et al. invoked the signiﬁcant contribution of
protein conformational transitions to the zymogen activation
mechanism [62]. Recently, Rosenblum et al. reported the ﬁrst
structural-dynamic model of pro-MMP-9 activation by tissue kallik-
rein protease [25]. Time-dependent structural and computationalanalyses of the nearest environment of the active site zinc ion revealed
the temporal sequence of pro-MMP-9 activation catalyzed by
proteolysis. The cysteine–zinc interaction that maintains enzyme
latency was disrupted via active site proton transfers (at the cysteine
switch) that mediate transient metal-protein coordination events and
the eventual binding of water. Remarkably, these events ensue as a
direct result of complexation of pro-MMP-9 and kallikrein. They occur
prior to proteolysis and result in the eventual dissociation of the pro-
peptide from the catalytic site. This study demonstrated the synergism
among long-range protein conformational transitions, the local
structural rearrangements, and the ﬁne atomic events that take
place in the process of zymogen activation. In addition, this work
provided experimental evidence for the long-sought role of protein
intra-domain communication in mediating catalysis.
A recent report by Geurts et al. [58] investigated possible
molecular pathways of pro-MMP-9 activation associated with hemor-
rhagic and hemolytic diseases. More speciﬁcally, Geurts et al. studied
whether and how hemoglobin and its derivatives might activate pro-
MMP-9. Incubation of pro-MMP-9 with hemin or β-hematin, the core
constituent of hemozoin or malaria pigment, resulted in differential
autocatalysis of the pro-peptide, mediated by allosteric interaction
with the hemopexin domain. The cleavage catalyzed by β-hematin
coincides with the ﬁrst cleavage by stromelysin-1/matrix metallo-
proteinase-3. This novel autocatalytic activation mechanism of pro-
MMP-9 by hemin and β-hematin identiﬁed the hemopexin domain as
the key functional and allosteric regulatory domain. It was proposed
that the hemin/β-hematin–hemopexin molecular interaction desta-
bilizes the enzyme pro-domain via protein conformational changes
prior to autocatalysis [58].
Interestingly, MMP autocatalytic activation was proposed to be a
key physiological mechanism mediated by allosteric protease-sub-
strate/effector interactions [21]. These activation mechanisms may be
associated with enzyme compartmentalization (e.g., cell surface-
tethered enzymes) that apparently regulates the speciﬁcity of MMPs
towards their substrates by increasing the local concentrations at a
speciﬁc location. Several examples were reported for secreted MMPs
including the interactions of MMP-9 with CD44, MMP-1 with α2β1
integrin, and MMP-7 with surface proteglycans [63–67]. CD44, α2β1
integrin, and proteglycans were suggested as accessory factors that
mediate zymogen activation via allosteric molecular interactions as
well as serving as “adaptor” molecules that bring together proteinase
and substrate at effective concentrations [21]. Although accumulating
evidence highlights the importance of allosteric activation mechan-
isms in pathological processes, the molecular and structural bases
leading to zymogen conversion remain elusive. In this respect,
structural-dynamic and biophysical information on MMP-protein/
effector interactions is critical for assigning the molecular mechan-
isms associated with allosteric control.
3.2. MMP substrate interactions
Degradation of interstitial ﬁbrillar collagen types I, II, and III in
embryogenesis, morphogenesis, tissue remodeling, and the progres-
sion of diseases is thought to be mediated by collagenases. Triple-
helical collagens are resistant to most proteinases, but collagenases
cleave them into speciﬁc 3/4 and 1/4 fragments. This process is
critical for collagenolysis in the tissue and for tissue damage in
degenerative diseases. Of the 23MMPs found inman, 5 are considered
to have collagenolytic activity: collagenase 1 (MMP-1), collagenase 2
(MMP-8), collagenase 3 (MMP-13), gelatinase A (MMP-2), and
membrane-bound MT1-MMP. The collagenases share a similar
domain arrangement, a pro-domain, a catalytic domain with Zn2+
forming the active site, a linker region, and a hemopexin domain.
MMP-2 contains a ﬁbronectin repeat domain (also designated as a
collagen-binding domain, CBD) for binding collagen or gelatin
substrates (Figs. 1 and 2). The CBD domain in MMP-2 was shown to
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the collagen α1 chain and cleaving the collagen α2 chain [68,69]. The
catalytic domain alone can cleave non-collagen substrates, but for the
enzyme to cleave triple-helical ﬁbrillar collagen, the presence of the
hemopexin domain is essential [70–72]. The catalytic and hemopexin
domains cooperate to ﬁrst locally unwind the triple-helical structure
of collagen before cleavage takes place [70]. The crystal structure of
human pro-MMP-1 showed that, relative to the active form of the
enzyme, hemopexin domain canmove relative to the catalytic domain
[50]. Thus, the independent movements of the enzyme terminus
domains may play a role in collagen processing and enzyme-collagen
translocation interactions [54].
The pivotal role of the MMP hemopexin domain was also
demonstrated for non-collagenous substrates. For example, ‘exosite
scanning’ using the hemopexin domain of MMP-2 as bait in the yeast
two-hybrid system, initially identiﬁed the CC-chemokine, monocyte
chemoattractant protein -3 (MCP-3), as a potential substrate of MMP-
2. The hemopexin domain of MMP-2 plays an important role in the
binding of MCP-3 substrate, an interaction that markedly enhances
catalysis. Removal of the hemopexin domain reduced the turnover
rate (Kcat/Km) of MCP-3 from ∼8000 M−1 S−1 to ∼500 M−1 S−1,
thus revealing the importance of this exosite in promoting catalysis.
Moreover, the isolated hemopexin domain competitively inhibits the
cleavage of MCP-3 by MMP-2 [73]. Other MCPs are also cleaved
efﬁciently by MMPs typically at the same position. It remains to be
determined whether other MMPs also bind these chemokines via an
exosite on the hemopexin domain [74]. Notably, the precise processing
of all MCPs by multiple members of the MMP family was shown to
control inﬂammatory responses in vivo [74].
Similarly, the importance of the hemopexin domain was also
demonstrated for the binding of CXC chemokine stromal cell-derived
factor 1 (SDF-1) α and β by MMP-2. A tetrapeptide from the
aminoterminal end of these chemokines is removed by MMP-2 and
other MMPs (including MMP-1, MMP-2, MMP-3, MMP-9, MMP-13,
and MMP-14) [75]. Efﬁcient proteolysis results from interaction with
an exosite on the hemopexin domain that at least partially overlaps
with the binding site of MCP-3. Similarly, an excess of hemopexin
domain completely inhibited MMP-2 cleavage of SDF-1α. Cleavage of
SDF-1α and -1β results in loss of chemotactic capacity [75]. In the
brain, cleavage of SDF-1α by HIV-induced MMP-2 results in a highly
neurotoxic protein, which induces neuronal apoptosis and neurode-
generation [76].
Another example highlighting the importance of the hemopexin
domain in substrate recognition and proteolysis was reported by
Monaco et al. [77] describing the cleavage of ﬁbrinogen by MMP-2.
MMP-2 interacts through its hemopexin domain with ﬁbrinogen, as
established by the observation that fragmentation of ﬁbrinogen by
MMP-2 is signiﬁcantly inhibited by addition of the isolated hemopexin
domain. The MMP-2 variant without the hemopexin domain exhibits
20-fold reduced enzymatic efﬁciency, and an additional ﬁbrinogen
fragment, which is not observed upon cleavage of full-length MMP-2,
is formed. These ﬁndings suggest a role for the hemopexin domain of
MMP-2 in correct recognition of ﬁbrinogen [77], as observed forMMP-
8 toward collagen I [78]. Importantly, otherMMPs (e.g., MMP-8, MMP-
12, MMP-14, and MMP-26) were shown to cleave ﬁbrinogen [79];
however, more research is necessary to unravel the molecular modes
by which these enzymes recognize and process ﬁbrinogen [79].3.3. Functional MMP dimerization
Homodimerization/multimerization has emerged as an important
mechanism for regulating the activation and activity of MMPs, in
particular, MT1-MMPandMMP-9 [20,80,81]. It was demonstrated that
MMP ancillary domains, including the hemopexin, transmembrane,
and cytoplasmic domains, are required for MT1-MMP to form a homo-oligomer complex, which is important for MT1-MMP cell surface
activation of pro-MMP-2 [61,80,82,83] and for collagenolysis [84].
Pro-MMP-2 activation by MT1-MMP is considered to be an
important step in tumor invasion [85]. The activation steps include a
tri-molecular complex formation of MT1-MMP, TIMP-2, and pro-
MMP-2, implying that an allosteric component is involved in this
mechanism. In the activation process, MT1-MMP forms a complex
with its endogenous inhibitor, TIMP-2, together forming a receptor
complex for pro-MMP-2 on the cell surface [86]. TIMP-2 binds to the
catalytic site of MT1-MMP through its inhibitory site in the N-terminal
domain, leaving the C-terminal domain of TIMP-2 to bind by means of
a hydrophobic interaction with the hemopexin domain of pro-MMP-2
[87,88]. Within this ternary complex, TIMP-2 functions as an adaptor
molecule, mediating the binding of MT1-MMP to pro-MMP-2.
Presenting pro-MMP-2 in this triad complex is thought to induce
conformational changes in the enzyme pro-peptide and to prepare it
for positional catalysis via an adjacent active MT1-MMP. This process
is driven by molecular interactions of two MT1-MMP molecules via
their hemopexin and/or transmembrane/cytoplasmic domains
[61,82]. Interfering with the process of MT1-MMP homodimer
formation results in inhibition of pro-MMP-2 activation [80,89].
Remarkably, it was proposed that the ﬂexibility of the MT1-MMP
linker domain and its molecular architecture plays a role in facilitating
the correct orientation of the ecto-domains required for positional
catalysis [82,90,91].
Utilization of such allosteric molecular control tomodulate MMP-2
zymogen activation was recently demonstrated by Ingvarsen et al.
[83]. Efﬁcient activation of pro-MMP-2 on the surface of ﬁbroblasts
and ﬁbrosarcoma cells (expressing both pro-MMP-2 and MT1-MMP)
could be induced by an anti-MT1-MMP hemopexin domain mono-
clonal antibody (mAb-1) [83]. mAb-1 stabilizes MT1-MMP cell dimers
and thus increases the efﬁciency of pro-MMP-2 activation on the cell
surface. This work demonstrates the potential of using allosteric
molecular control (such as MMP dimerization) to modulate MMP
functionality and efﬁcient catalysis.
MMP-9 also exists as a monomeric and homodimeric molecule
[92], in both its latent and active forms. Both monomeric and dimeric
forms of MMP-9 have been identiﬁed in a variety of cells (including
normal and tumor cells) and in biological ﬂuids and tissues, indicating
that both forms are physiologically relevant. Dimerization/multi-
merization is mediated by the carboxyterminal domains of MMP-9
and occurs intracellularly [81]. The biological functional role of the
MMP-9 dimer has not been elucidated. There are contradictory reports
concerning whether dimeric MMP-9 is able to form complexes with
TIMP-1 or whether the MMP-9-TIMP-1 complex is incompatible with
MMP-9 homo dimerization [81,92]. It has been shown that dimeriza-
tion signiﬁcantly decreases the activation rate of pro-MMP-9 by
stromelysin (MMP-3) [81]. Thus, it is tempting to speculate that
ﬂuctuations in the relative amounts of latent monomer and dimer
secreted into the extracellular milieu play a post-translation regula-
tory role in MMP-9-dependent proteolysis.
Since dimerization/multimerization is reduction-sensitive, it is
believed to be disulphide linked [81,92]. In the hemopexin domain,
the two conserved cysteine residues Cys516 and Cys704 form a
disulﬁde bridge connecting the ﬁrst and fourth blade of the propeller
structure, thus excluding a direct role of these cysteine residues in
dimerization/multimerization. It was suggested that the dimerization
is mediated by disulﬁde bonds involving Cys468 (in the OG domain)
and/or Cys674 (in the hemopexin domain), both of which are unique
to MMP-9 [81,92]. Yet, based on studies of site-speciﬁc mutagenesis,
participation of these cysteine residues is also excluded. The identities
of the cysteine residues that predispose MMP-9 to dimerization
remain unknown. Deletion mutants of MMP-9 lacking the OG domain
are only observed as monomers, indicating that the OG domain is
essential for dimerization/multimerization [60]. Furthermore, the
potential of isolated hemopexin domains of MMP-9 to undergo
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reported the crystal structure of the MMP-9 hemopexin domain,
demonstrating that the hemopexin domain of MMP-9 can dimerize by
noncovalent and mainly hydrophobic interactions at the fourth blade
of this domain. Furthermore, a peptide that selectively binds the
hemopexin domain of MMP-9 inhibited dimerization of the MMP-9
recombinant hemopexin domain [94].
4. Allosteric inhibition of MMPs
MMPs serve as attractive targets for the design of potent inhibitors.
Inhibition of MT1-MMP as well as other MMPs for the treatment of
diseases, such as cancer, arthritis, and other diseases associated with
tissue remodeling, has become an area of intense interest in the
pharmaceutical industry in the last two decades [95]. Yet, despite
tremendous efforts to explore individual members of this target
family, along with multiple inhibitor classes, effective drugs for
inhibiting individual MMPs have not yet emerged. The increasing
availability of high-resolution X-ray crystal structures for many
members of this protein family makes MMPs ideally suited for
structure-based design approaches by targeting the catalytic zinc ion
[35,36,96,97]. Unfortunately, careful analysis of X-ray crystal struc-
tures has not suggested any simple solutions. The design of speciﬁc
antagonists as drug candidates has proven difﬁcult since all MMPs and
related enzymes share a highly homologous catalytic domain.
Importantly, most MMP inhibitors target the conserved catalytic
zinc site of all MMPs — even those that prevent tumor progression
[42]. Disappointing results from clinical trials of small-molecule MMP
inhibitors have prompted reconsideration of strategies for more
enzyme-speciﬁc MMP inhibition by targeting the “exodomain–
substrate” interactions, as reviewed by Overall and Lopez-Otin [40].
Such exosites or allosteric sites have been proposed to represent
unique opportunities for the design of selective inhibitors [98–100]. A
recent report by Gioia et al. [116] demonstrated that proteolytic
processing of collagen IV is mediated by catalytically inactive domain
(i.e. the CBD). The authors suggested that MMP-2 and MMP-9 might
cooperate in degrading collagen IV even when either one is inactive.
This observation reinforces the idea of exosite targets for MMP
inhibitors, and highlights the importance of identifying and targeting
multiple substrate recognition sites in themodular structure of MMPs.
Along these lines, high-throughput screening strategies have been
employed to discover potential selective MMP exosite inhibitors.
In order to discover potentially selective MMP-13 exosite
inhibitors, Lauer-Fields et al. recently employed a high-throughput
screening approach utilizing a triple-helical FRET substrate [101].
Since triple-helical peptide substrates have distinct conformational
features that interact with protease secondary binding sites (exo-
sites) [102], these substrates could allow for the identiﬁcation of
allosteric inhibitors. This experimental approach yielded highly
selective MMP-13 inhibitors [103] mechanistically distinct from the
other inhibitors identiﬁed. Since this inhibitor was more effective
against MMP-13 triple-helical peptidase activity compared with
MMP-13 single-stranded peptidase activity, it was suggested that it
may bind to an MMP-13 collagen-binding exosite. Nevertheless,
further studies are needed to evaluate the precise mechanism under-
lying its action.
Efﬁcient inhibition of collagenolysis has been shown by targeting
CBD (ﬁbronectin domain) of MMP-2, thus blocking CBD-substrate
interactions. Recombinant CBD was used as bait to screen a random
combinatorial peptide library. This screen identiﬁed a CBD-binding
peptide with high identity with a short segment of an α 1(I) collagen
chain [104]. The potential speciﬁcity of this peptidewas demonstrated
by its exhibiting no effect on the collagenolitic activity of MMP-8, a
collagenase lacking the CBD. Thus, blocking CBD-substrate interac-
tions in MMP-2 and MMP-9 provides a unique opportunity to identify
allosteric inhibitors targeting speciﬁc collagenolitic activitiesmediated by these two enzymes [68,105,106]. Further efforts are
needed to identify the precise binding site residues on the CBD that
are critical for collagen binding in MMP-2 so that a rational,
structurally based approach may be applied to chemically modify
and develop inhibitors with optimal CBD-binding and MMP-2
inhibitory properties.
MMP inhibition strategies, based on blocking exosite-mediated cell
surface interactions and activation were also suggested [40]. For
example, several MMPswere shown to interact with integrins through
their C-terminal domains [64,94,107]. Bjorklund et al. [94], using
phage display peptide libraries with pro-MMP-9 or the recombinant
C-terminal domain as bait, developed an inhibitory peptide that binds
selectively to the hemopexin domain of MMP-9. Interestingly, the
binding of the inhibitory peptide to the hemopexin domain could not
be competed out by TIMP-1. The C-terminal domain binding peptide
bears similarity to a sequence found in the stalk of the integrin β5
chain and inhibits the association of the MMP-9 hemopexin domain
withανβ5 integrin. Importantly, unlike the small-molecule active site-
directed inhibitors, the peptide does not directly affect the proteolytic
activity of MMP-9. Instead, it interferes speciﬁcally with integrin-
mediated interactions. Nevertheless, it prevents proenzyme activa-
tion, cell migration, and tumor cell growth in vivo. This further
indicates that selective MMP inhibitors can be designed to block
speciﬁc functional interactions mediated by MMP exosite interactions
with co-factors and protein partners.
A different and more complex strategy to improve speciﬁcity is
represented by multifunctional inhibitors able to bind different
enzyme domains through their different chemical moieties. Accord-
ingly, the speciﬁcity of an inhibitor may be improved if it interacts
bothwith the active site andwith exosites unique to individual MMPs.
An initial attempt has been carried out by Farlow et al. [108] by
employing a chimeric protein consisting of streptavidin fused to a
cyclic decapeptide, which has been shown to be a good inhibitor of
MMP-2. Jani et al. [109] explored this possibility with MMP-2; they
attempted to design inhibitors that interact with both the active site
and exosites such as the ﬁbronectin domain of the MMP-2 enzyme.
Hydroxamate-based inhibitors of MMP-2 were extended with gelatin-
like structures known to bind to the collagen-binding ﬁbronectin
domain of MMP-2. However, selectivity was not enhanced by
interaction with the ﬁbronectin repeats. It seems likely that the
failure to exploit interaction with the ﬁbronectin domain is because
the ﬁbronectin domain and the catalytic domain of MMP-2 tumble
independently. Therefore, only a tiny fraction of the conformational
isomers can bind peptide hydroxamates via both the active site and
the ﬁbronectin domain(s) [109].
5. Function blocking antibodies of MMPs
Numerous reports emphasize the need for highly selective MMP
inhibitors for realizing the clinical potential of MMPs as targets for
drug design [2,43]. Antibodies (Abs) are well established as
therapeutic agents for diverse diseases [110] including cancer,
autoimmune disorders, and infectious diseases. The design of function
blocking Abs targeting highly speciﬁc MMP regulatory sites is an
attractive proposition for selectively controlling enzyme activity in
vitro and in vivo. Because of their ability to selectively bind closely
related antigens, Abs provide an excellent scaffold for creating
function blocking inhibitors for individual MMPs. Conceptually, Abs
could inhibit protease activity directly by binding at or near the active
site to block substrate access or indirectly by binding to regions that
are allosterically linked to the active site region. Alternatively, Ab-
based protease/MMP inhibitors can be designed to target extracata-
lytic/ancillary domains such as the hemopexin domain, the ﬁbronec-
tin domain, or the linker region to block substrate-speciﬁc binding
sites. This may enable the modulation of certain enzymatic and non-
enzymatic activities for a given MMP. In this respect, highly selective
Fig. 4. Target allosteric protein sites used for the generation of anti-MMP function blocking Abs. A. Interaction site of anti-MMP-9 mAb REGA-3G12 as depicted in the structure of the
catalytic and ﬁbronectin domains of MMP-9 (PDB 1L6J). The site of interaction as analyzed by biochemical analysis [112] is shown in red. Importantly, the antibody interacts with the
catalytic domain surface, but not with the zinc active site (zinc ion represented as orange sphere ligated by three conserved histidines shown as sticks). B. The catalytic domain of
MT1-MMP (PDB 1BUV) is shown in cartoon and surface representation (grey), the catalytic zinc ion is shown as orange sphere ligated by three conserved histidines (shown as sticks).
The two exposed loops that were used to generate anti-MT1-MMP antibodies are colored in red andmagenta respectively. These surface loops reside away from the catalytic zinc site.
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emerged from the chemistry and protein conformation of exosite
domains of individual MMP. Using this approach it may be possible to
target multiple functional sites on given enzyme.
The most selective inhibitor of human gelatinase B/MMP-9
developed to date is an mAb, REGA-3G12. It binds with high afﬁnity
and inhibits the biological activity of gelatinase B/MMP-9 but not
gelatinase A/MMP-2. The antigen used to prepare mAb REGA-3G12 is
human gelatinase B, which is produced from neutrophils [111].
Importantly, REGA-3G12 was found to recognize the aminoterminal
part of the catalytic domain of MMP-9 but not the zinc ion binding
part [112] (Fig. 4A). It is unlike most small-sized inhibitors that
directly interact with the catalytic zinc ion for inhibition. The high
afﬁnity and selectivity of REGA-3G12 may be attained by interaction
with a considerable part of the catalytic domain surface.
Remarkably, the diversity of protease surface loops makes them
attractive exosite targets for the design of function blocking Abs.
Accordingly, highly selective anti-MT1-MMP antibodies were gener-
ated against exposed and accessible loops within the MT1-MMP
catalytic domain [113] (Fig. 4B). These anti-MT1-MMP mAbs were
shown to inhibit MT1-MMP proteolytic activity and have anti-
angiogenic functional properties as well as impaired tumor cell
invasion characteristics (the functional properties of these antibodies
are summarized in [114]). The mechanism underlying the inhibitory
activity of these antibodies is yet to be characterized.
Recently a potent and highly selective MT1-MMP inhibitory
antibody was discovered by Dyax Corp. using phage display
technology with the catalytic domain of MMP-14 as a target [115].
The selected antibody, DX-2400, inhibited MMP-14 with Ki in the sub-
nanomolar range (Ki=0.8 nmol/L) in a competitive manner,
indicating direct blockage of the catalytic site. Notably, the antibody
did not inhibit activity of a panel of secreted human MMPs or TACE as
well as other MT-MMPs. Functionally, DX-2400 blocked pro-MMP-2
processing on tumor and endothelial cells, inhibited angiogenesis, and
slowed tumor progression and the formation of metastatic lesions
[115]. Overall, these examples emphasize the therapeutic potential ofspeciﬁc antibody-based MMP inhibitors. However, the potential of
this strategy is yet to be discovered and realized in vivo.
6. Summary
MMPs are involved in the regulation of cell–cell and cell–ECM
interactions in both physiological and pathological states. As such,
monitoring the enzymatic activity of individual MMPs by antagonist
molecules is highly sought after for revealing their biological
pathways and for controlling their activities in vivo. This review
emphasizes the fact that MMPs possess modular domain organization
and signiﬁcant molecular ﬂexibility. These molecular properties
enable MMPs to interact and process a broad range of substrates
possessing different molecular natures and architectures. However,
themolecular bases bywhichMMPs interact with their substrates and
protein partners remain elusive. Nevertheless, our current under-
standing indicates that MMP activities are regulated by allosteric
molecular control. Here we discussed the importance of revealing the
structural and functional bases leading to allosteric control of MMPs in
vitro and in vivo. In addition, we highlighted potential exosite or
allosteric protein regions as potential targets for the design of highly
selective function blocking MMP inhibitors.
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